Published in Bioinformatics on January 28, 2009
SnoopCGH: software for visualizing comparative genomic hybridization data. Bioinformatics (2009) 0.87
FISH Oracle: a web server for flexible visualization of DNA copy number data in a genomic context. J Clin Bioinforma (2011) 0.82
A multi-sample based method for identifying common CNVs in normal human genomic structure using high-resolution aCGH data. PLoS One (2011) 0.75
The hallmarks of cancer. Cell (2000) 113.05
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics (2003) 82.89
Detection of large-scale variation in the human genome. Nat Genet (2004) 49.18
The diploid genome sequence of an individual human. PLoS Biol (2007) 44.80
Large-scale copy number polymorphism in the human genome. Science (2004) 34.64
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data. Genome Res (2007) 19.07
A high-resolution survey of deletion polymorphism in the human genome. Nat Genet (2005) 16.99
Integrated genotype calling and association analysis of SNPs, common copy number polymorphisms and rare CNVs. Nat Genet (2008) 15.89
Common deletion polymorphisms in the human genome. Nat Genet (2006) 15.66
Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet (2008) 15.51
A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics (2007) 14.25
High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. Genome Res (2006) 10.45
QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res (2007) 10.08
Large-scale genotyping of complex DNA. Nat Biotechnol (2003) 10.00
Common deletions and SNPs are in linkage disequilibrium in the human genome. Nat Genet (2005) 9.61
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
Copy-number variation and association studies of human disease. Nat Genet (2007) 8.50
Analysis of array CGH data: from signal ratio to gain and loss of DNA regions. Bioinformatics (2004) 8.29
Psoriasis is associated with increased beta-defensin genomic copy number. Nat Genet (2007) 8.07
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Array comparative genomic hybridization and its applications in cancer. Nat Genet (2005) 6.69
Whole-genome genotyping with the single-base extension assay. Nat Methods (2006) 6.66
Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet (2007) 5.28
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
The fine-scale and complex architecture of human copy-number variation. Am J Hum Genet (2008) 5.08
CARAT: a novel method for allelic detection of DNA copy number changes using high density oligonucleotide arrays. BMC Bioinformatics (2006) 2.82
PLASQ: a generalized linear model-based procedure to determine allelic dosage in cancer cells from SNP array data. Biostatistics (2006) 2.82
CGHPRO -- a comprehensive data analysis tool for array CGH. BMC Bioinformatics (2005) 1.71
On the analysis of copy-number variations in genome-wide association studies: a translation of the family-based association test. Genet Epidemiol (2008) 1.47
Simultaneous discovery and testing of deletions for disease association in SNP genotyping studies. Am J Hum Genet (2007) 1.23
Rank-statistics based enrichment-site prediction algorithm developed for chromatin immunoprecipitation on chip experiments. BMC Bioinformatics (2006) 1.20
A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics (2008) 1.11
Integrative genomics viewer. Nat Biotechnol (2011) 42.83
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet (2012) 11.09
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 6.39
The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet (2012) 6.15
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80
Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med (2006) 4.63
Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. J Clin Oncol (2010) 4.19
Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet (2014) 4.13
Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A (2008) 3.30
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics (2012) 2.94
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood (2005) 2.81
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A (2009) 2.77
Retracted Cytohesins are cytoplasmic ErbB receptor activators. Cell (2010) 2.74
Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res (2008) 2.48
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res (2007) 2.45
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A (2006) 2.17
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol (2011) 2.10
Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res (2011) 2.06
A crucial requirement for Hedgehog signaling in small cell lung cancer. Nat Med (2011) 1.97
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res (2008) 1.95
High expression levels of total IGF-1R and sensitivity of NSCLC cells in vitro to an anti-IGF-1R antibody (R1507). PLoS One (2009) 1.93
Genome-wide functional synergy between amplified and mutated genes in human breast cancer. Cancer Res (2008) 1.82
Benchmarking of mutation diagnostics in clinical lung cancer specimens. PLoS One (2011) 1.65
Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment. J Clin Oncol (2013) 1.65
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res (2012) 1.65
Major copy proportion analysis of tumor samples using SNP arrays. BMC Bioinformatics (2008) 1.62
Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res (2006) 1.58
Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res (2012) 1.53
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res (2010) 1.43
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest (2013) 1.41
ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res (2011) 1.40
Problems and promises of targeted therapy for Hodgkin's lymphoma. Nat Clin Pract Oncol (2005) 1.38
Common variants in the ENPP1 gene are not reproducibly associated with diabetes or obesity. Diabetes (2006) 1.26
A framework for identification of actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A (2012) 1.21
CD74-NRG1 fusions in lung adenocarcinoma. Cancer Discov (2014) 1.19
Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov (2013) 1.18
Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res (2010) 1.17
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). PLoS One (2008) 1.16
A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing. Cancer Lett (2005) 1.12
Blood-based gene expression signatures in non-small cell lung cancer. Clin Cancer Res (2011) 1.09
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway. J Thorac Oncol (2008) 1.09
Part II: Hodgkin's lymphoma--diagnosis and treatment. Lancet Oncol (2004) 1.08
Therapeutic targeting of a robust non-oncogene addiction to PRKDC in ATM-defective tumors. Sci Transl Med (2013) 1.05
AATF/Che-1 acts as a phosphorylation-dependent molecular modulator to repress p53-driven apoptosis. EMBO J (2012) 1.02
Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data. Genome Biol (2015) 1.01
From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential. Blood (2005) 0.98
Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J Mol Biol (2005) 0.96
Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer (2011) 0.94
Downregulation of 18F-FDG uptake in PET as an early pharmacodynamic effect in treatment of non-small cell lung cancer with the mTOR inhibitor everolimus. J Nucl Med (2009) 0.93
Epidermal growth factor receptor (EGFR) signaling and covalent EGFR inhibition in lung cancer. J Clin Oncol (2012) 0.93
CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest (2016) 0.92
The Krüppel-like factor 11 (KLF11) Q62R polymorphism is not associated with type 2 diabetes in 8,676 people. Diabetes (2006) 0.85
Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling. PLoS One (2010) 0.85
Standardized high-throughput evaluation of cell-based compound screens. BMC Bioinformatics (2008) 0.85
Synthesis and biological evaluation of 4-anilinoquinolines as potent inhibitors of epidermal growth factor receptor. J Med Chem (2010) 0.84
Spatial Tumor Heterogeneity in Lung Cancer with Acquired Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Resistance: Targeting High-Level MET-Amplification and EGFR T790M Mutation Occurring at Different Sites in the Same Patient. J Thorac Oncol (2015) 0.82
Allelic losses on chromosome 6q25 in Hodgkin and Reed Sternberg cells. Cancer Res (2003) 0.81
CGARS: cancer genome analysis by rank sums. Bioinformatics (2014) 0.80
Efficient activation of autologous tumor-specific T cells: a simple coculture technique of autologous dendritic cells compared to established cell fusion strategies in primary human colorectal carcinoma. J Immunother (2007) 0.79
Identification and further development of potent TBK1 inhibitors. ACS Chem Biol (2015) 0.77
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors. J Thorac Oncol (2010) 0.76
Systematically linking drug susceptibility to cancer genome aberrations. Cell Cycle (2009) 0.76
The major subtypes of human B-cell lymphomas lack mutations in BCL-2 family member BAD. Int J Cancer (2006) 0.75
Targeting gain of function and resistance mutations in Abl and KIT by hybrid compound design. J Med Chem (2013) 0.75
Retraction Notice to: Cytohesins Are Cytoplasmic ErbB Receptor Activators. Cell (2016) 0.75